87.68

0.06% 0.05

Monopar Therapeutics Inc (MNPR)

Overview News Price History Financials Discussions Forecast

Monopar Therapeutics Inc stock is traded at $87.68, with a volume of 310.27K. It is up +0.06% in the last 24 hours and up +40.02% over the past month. Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Previous Close:

$87.63

Open:

$87.64

24h Volume:

310.27K

Relative Volume:

1.81

Market Cap:

$587.37M

Revenue:

Net Income/Loss:

$-14.99M

P/E Ratio:

-42.43

EPS:

-2.0665

Net Cash Flow:

$-10.01M

1W Performance:

+29.95%

1M Performance:

+40.02%

6M Performance:

+27.50%

1Y Performance:

+150.44%

1-Day Range:

$85.70

$92.25

1-Week Range:

$66.83

$94.83

52-Week Range:

$29.18

$105.00

Monopar Therapeutics Inc Stock (MNPR) Company Profile

Name

Monopar Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (615)

Phone

(847) 388-0349

Address

1000 SKOKIE BLVD SUITE 350, WILMETTE

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

MNPR's Discussions on Twitter

Compare MNPR vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MNPR Monopar Therapeutics Inc	87.68	587.37M	0	-14.99M	-10.01M	-2.0665
VRTX Vertex Pharmaceuticals Inc	491.34	124.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	632.90	66.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	887.18	55.17B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.37	38.90B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	182.08	38.71B	742.00K	-1.37B	-1.07B	-7.0731

Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-09-26	Initiated	Morgan Stanley	Overweight
Nov-14-25	Downgrade	Raymond James	Strong Buy → Outperform
Nov-10-25	Initiated	Leerink Partners	Outperform
Oct-13-25	Initiated	Barclays	Overweight
Sep-09-25	Initiated	BTIG Research	Buy
Sep-03-25	Initiated	Oppenheimer	Outperform
Sep-03-25	Initiated	Raymond James	Strong Buy
Aug-26-25	Resumed	H.C. Wainwright	Buy
Jul-07-25	Initiated	Cantor Fitzgerald	Overweight
Jun-23-25	Initiated	Chardan Capital Markets	Buy
Mar-19-25	Resumed	Piper Sandler	Overweight
Jan-10-25	Initiated	Piper Sandler	Overweight
Oct-11-24	Initiated	Rodman & Renshaw	Buy
Jan-28-21	Initiated	ROTH Capital	Buy

View All

Monopar Therapeutics Inc Stock (MNPR) Latest News

05:54 AM

Enterprise value to EBITDA forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView

05:54 AM

03:10 AM

Enterprise value to revenue forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView

03:10 AM

01:57 AM

Enterprise value to revenue forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView

01:57 AM

Jun 27, 2026

Price to sales forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView

Jun 27, 2026

Price to earnings forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView

Jun 27, 2026

Monopar Presents Phase 3 FoCus Data Showing Neurologic and Global Benefit with ALXN1840 - TradingView

Jun 26, 2026

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease - The Manila Times

Jun 26, 2026

ALXN1840 Phase 3 data back NDA plan for Wilson disease, Monopar (NASDAQ: MNPR) - Stock Titan

Jun 26, 2026

Monopar’s Wilson disease drug shows stronger neurologic gains in Phase 3 - Stock Titan

Jun 26, 2026

Monopar Therapeutics Inc Actuals & Estimates (LS:A40JML) - TradingView

Jun 26, 2026

Monopar Therapeutics Inc Actuals & Estimates (DUS:1IY0) - TradingView

Jun 26, 2026

A40JML Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

1IY0 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 24, 2026

NDA submission progress for ALXN1840 in Wilson disease sends Monopar Therapeutics stock up 7.61% - Traders Union

Jun 24, 2026

Monopar Therapeutics Inc Cash Flow – DUS:1IY0 - TradingView

Jun 24, 2026